Dr. Lioi Susanna
Dr. Susanna Lioi
Operative Unit: Medical Retina Operating Unit
Clinical activity: Dr. Susanna Lioi since 2010 has been working for Medical Retinal Unit ‘Fondazione G.B.Bietti-IRCCS’ in clinical-scientific activities.
Mainly she works for clinical trials as Study- cordinator and Co- Investigator and her main interests concern Orthoptics , Low vision and Visual Rehabilitation and Instrumental diagnostic tests for Retinal deseases.
She graduated in Orthoptics and Ophthalmological Assistance at Rome University ‘Tor Vergata’ in 2009 with 110/110 with Honor.
Since 2010 Researcher for Medical Retinal Unit ‘Fondazione G.B.Bietti-IRCCS, via Livenza 3, 00198, Rome
- A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
- Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema
- A 12-Month, multicenter, randomized, parallel group study to compare the efficacy and safety of Ozurdex versus Lucentis in patients with branch retinal vein occlusion.
- A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema
- A6-month,Phase II, Double-masked, Multicenter, Randomized,Placebo- controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% and 2%) Twice Daily for the Treatment of Center- involving Clinically Significant Macular Edema Associated with Diabetic Retinopathy . (FOVEA)
- A multicentric open-label randomized study comparing the efficacy and safety of 700 g dexamethasone segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema
- A 12-month, phase IIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration (TREND)
- A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
- A PHASE 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovista ( anti pdgf-b pegylated aptamer) administered in combination with Lucentis compared to lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
- A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration.
- A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
- Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients
With Neovascular Age-related Macular Degeneration
- An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
- Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study
- A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion (CENTERA)